The news of the European Commission, Which has finally approved a drug treatment as a basis for therapy Multiple Sclerosis, Has rekindled interest in this disease. L Aism (Italian Multiple Sclerosis Association) took advantage of so, and we with you, to spread the disease characteristics, for better understanding and possibly prevention.
Today we begin with some general information about the disease and new treatment (Fingolimod): The Multiple Sclerosis is a multifactorial disease, which is due to two components of factors, genetic and environmental, that trigger a reaction immune system against myelin (Sheath that surrounds most of the nerve fibers and may ensure a high rate of transmission of nerve impulses.)
As reported in the Aims The Multiple Sclerosis can occur in various ways, in fact the symptoms can vary from person to person and within the same individual some are repeated more frequently, either individually or simultaneously, without a predetermined criterion.
It occurs mainly in four types of clinical course (relapsing-remitting MS, secondary progressive, primary progressive and progressive-relapsing) With the addition of a fifth form characterized by a trend, termed ‘Benign MS’ .
It is not easy to predict with certainty what the long-term course of Multiple Sclerosis in the individual. In any event, whatever the form of the disease, lifespan of people with MS is not substantially different from that of others, and today MS diagnosis Who has the right approach and knowing the illness, the likelihood of achieving a significant degree of disability are much smaller than in the past, and of course increased the odds of maintaining a good quality of personal life, work and social life.
This should be facilitated by introduction of Fingolimod The first drug for the treatment of this disease that is taken orally, effective in reducing relapses, the risk of progression Disabilities and the number of brain lesions. L Aism, Italian Multiple Sclerosis Society, states that treatment with this drug has been approved by the EU only for the relapsing-remitting or severe relapsing-remitting MS to rapidly changing.
The introduction of Fingolimod, Whose commercial name is Gileno has not been an easy process: up to 2010 had been skeptics against it because it was found that it was associated with infections opportunities and macular edema.
In any case, patients who qualify must be cautious to hire and request to test all the different factors that make your individual case to make sure you do unpleasant consequences.